Immune Profiles and Circulating Tumor Cell Status Following Prostate Cryotherapy

Immune Profiles and Circulating Tumor Cell Status Following Prostate Cryotherapy

The change of immune profiles and existence of circulating tumor cells following prostate cryotherapy may be correlated with the clinical outcome.

Inclusion Criteria:

• Age>20 years
• Histopathology-proven prostate adenocarcinoma
• Non-metastatic localized disease
• Subjects have chosen their curative, definitive treatments for prostate cancer prior to enrolling for the study
• Subjects are willing to sign the informed consent and agree to comply with the study procedures

Exclusion Criteria:

• Chronic use (> 2 weeks) of > 10 mg/day of prednisone or prednisolone within 2 months of the screening (topical or inhalational corticosteroids are permitted)
• Concurrent use of immunosuppressive therapy, including: cyclosporine, antithymocyte globulin, or tacrolimus within 3 months of study entry
• Other conditions the investigators think may affect subjects' compliance